tPA adenovirus

Tissue plasminogen activator (tPA) is a key enzyme encoded by the PLAT gene in the human body, primarily responsible for catalyzing the conversion of plasminogen to plasmin. This fibrinolytic process is crucial for breaking down blood clots, making tPA a key drug in thrombolytic therapy. The tPA gene is located on chromosome 8 and encodes a serine protease that targets fibrin-bound plasminogen, thereby promoting localized fibrinolysis. Its structure comprises multiple domains, such as the finger domain, epidermal growth factor domain, Kringle domain, and protease domain, which contribute to its binding specificity and enzymatic activity. Recombinant tPA (rtPA) is widely used in the clinical treatment of acute ischemic stroke and myocardial infarction due to its ability to rapidly dissolve obstructive blood clots. However, its short half-life and the risk of bleeding complications necessitate precise dosing and monitoring.

Adenoviral vectors have emerged as effective gene delivery tools, and tPA adenovirus refers to recombinant adenoviruses genetically engineered to carry the tPA gene. These vectors utilize the natural tropism of adenoviruses to efficiently transduce various cell types, enabling targeted expression of tPA in specific tissues. In cardiovascular research, tPA adenovirus is used to study thrombolysis mechanisms, endothelial function, and vascular repair. Preclinical models have shown that tPA adenovirus has the potential for localized thrombolysis and reduced systemic side effects compared to intravenous rtPA. Furthermore, it holds promise for gene therapy in treating conditions such as deep vein thrombosis and pulmonary embolism. Beyond thrombosis, the applications of tPA adenovirus extend to cancer therapy, where it can modulate the tumor microenvironment by degrading the fibrin barrier, thereby enhancing drug penetration.